Luciano Serra

endOK is an IP-driven life sciences company specializing in the development of targeted, non-hormonal therapies for chronic pelvic pathologies, specifically Endometriosis and Adenomyosis. Our thematic alignment with the Summit’s focus is defined by our commitment to Translational R&D and the clinical validation of bioactive compounds. We bridge the gap between bench science and clinical application. Our innovation is anchored in the EndoGen® proprietary bioactive complex. Our R&D process follows a rigorous biotech-standard pathway: In-Vitro Validation: Conducted in collaboration with Mérieux NutriSciences to prove total suppression of pro-inflammatory cytokines (IL-6/TNF-α), outperforming traditional NSAIDs. Clinical Trials: Validated through human clinical studies demonstrating a 70.6% efficacy rate in pain modulation and an 88.2% patient satisfaction score. While our products are categorized as high-value nutraceuticals, our manufacturing and quality processes mirror pharmaceutical standards and we are looking to synergize with University and Research center to expand tests and IPs.